![]() "We believe that cost-effective clinical trial conduct and ability to achieve fast and large-scale patient recruitment is equally attractive to small biotech companies and to large pharma. ![]() Nikitin added, is to deliver affordable clinical trial solutions with quality and speed. Ockham CEO Jim Baker noted that Russlan "gives us an opportunity to increase our oncology patient recruitment and provide additional sites for our sponsors." It confirms the high value of our region for international clinical trial activities and affirms our confidence in the standards of quality currently achieved in our countries of operation." Nikolai Nikitin, Director of Russlan Clinical Research, said that "working in a partnership with a major U.S.-based CRO is an honor and a privilege for our organisation. The announcement was made in the wake of Ockham's recent expansion of Ockham's European operations based in the U.K., headed by industry veteran Anthony J. Ockham Development Group Inc., a global Contract Research (CRO) and Functional Service Provider (FSP) organization, announced recently its partnership with Russlan Clinical Research (– a specialist CRO conducting clinical trial activities in the Eastern European countries of Russia, the Ukraine, Latvia, Lithuania, Estonia, as well as some other Commonwealth of Independent States (CIS) such as Georgia or Moldova. ![]() Expansion continues on heels of recent establishment of EU office ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |